Late Toxicity of Radiotherapy and Chemotherapy in Hodgkin Lymphoma

News
Video

This interview examines treatment-related cardiotoxicity and the risk of second malignancy in patients with Hodgkin lymphoma.

Treatment-related cardiotoxicity and the risk of second malignancy in survivors of Hodgkin lymphoma who received radiation therapy or chemotherapy is an important consideration given the high cure rate for this disease.

In this interview, Flora van Leeuwen, PhD, of the Netherlands Cancer Institute, discusses strategies to reduce the risk of these late toxicities and highlights some of the key points from an education session she presented at the 58th Annual Meeting of the American Society of Hematology, held December 3–6 in San Diego, California.

Recent Videos
It may be critical to sequence BCL-2 inhibitors with BTK inhibitors for patients with mantle cell lymphoma in the relapsed/refractory setting.
Reducing the manufacturing time of CAR T-cell therapy may have a big impact on the treatment of patients with mantle cell lymphoma.
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
Related Content